Meshref Mostafa, Shaheen Nour, Diab Rehab Adel, Desouki Mariam Tarek, Amro Yara, Khairat Shiamaa M, Ali Mohamed, Ahmed Mahmoud Galal
Neurology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Ann Med Surg (Lond). 2022 Sep 16;82:104726. doi: 10.1016/j.amsu.2022.104726. eCollection 2022 Oct.
Hemorrhagic transformation of ischemic stroke is one of the most traumatic consequences of ischemic stroke. Therefore, deciding the optimal time for anticoagulant application and its effect on clinical outcome, recurrence and risk for hemorrhagic transformation are still in quarry. The European Heart Rhythm Association recommends the usage of anticoagulants after 3-4 days after a mild stroke, 6 days after moderate stroke and 12 days after a severe stroke.
In our case report, we present two patients who started full therapeutic anticoagulation of low molecular weight heparin from the first day after moderate ischemic stroke, warfarin was added later guided by INR and discharged on oral anticoagulants for associated AF. They improved clinically with improved motor function for both upper and lower limbs, sensation and gaze without any complication followed by serial CT.
As a result of this case report, clinical improvement has not been associated with hemorrhagic sequelae of anticoagulant administration on the first day. At this point, we recommend conducting a trial to study the effect of early application of anticoagulants from the first day on clinical outcome, recurrence, and hemorrhagic transfusion of stroke.
缺血性脑卒中的出血性转化是缺血性脑卒中最具创伤性的后果之一。因此,确定抗凝剂应用的最佳时间及其对临床结局、复发和出血性转化风险的影响仍存在疑问。欧洲心律协会建议在轻度卒中后3 - 4天、中度卒中后6天、重度卒中后12天使用抗凝剂。
在我们的病例报告中,我们展示了两名患者,他们在中度缺血性卒中后的第一天就开始了低分子量肝素的全剂量治疗性抗凝,随后在国际标准化比值(INR)的指导下加用华法林,并以口服抗凝剂治疗相关房颤出院。他们的临床症状得到改善,上下肢运动功能、感觉和凝视均有改善,连续CT检查未发现任何并发症。
根据本病例报告,第一天使用抗凝剂后的临床改善与出血后遗症无关。在这一点上,我们建议进行一项试验,研究从第一天开始早期应用抗凝剂对卒中临床结局、复发和出血性转化的影响。